Chinese venture capital firm Shiyu Capital has led a RMB1.97 billion (US$278.5 million) Series A financing round in Mabwell Biotech, a Shanghai-based innovative biopharmaceutical company. Oriental Fortune Capital, Loyal Valley Innovation Capital, Haitong Innovation Capital Management, Founder H Fund, Haurong Rongde Asset Management, Huajin Capital, Sincere Capital, Winfast Holding and other investors also participated in the new round. Mabwell Biotech is a Chinese innovative biopharmaceutical company based in Shanghai Zhangjiang Hi-Tech Park. Since its establishment in 2017, it has absorbed and newly established nine biopharmaceutical R&D and production enterprises.